Lisa Eidenschink Brodersen

6PUBLICATIONS
45CO-AUTHORS
Haematological tumoursMedical bacteriologyMedical infection agents (incl. prions)Infant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 24, 2026
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

|May 28, 2026
Measurable Residual Disease in Pediatric Acute Leukemia: Application and Interpretation of Current and Emerging Methodologies.

|Oct 22, 2025
Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Jason N Berman, Anupam Verma, Shelton Viola

|Oct 17, 2025
Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

C Michel Zwaan, Sarah K Tasian, Richard Aplenc

|Mar 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.

Jessica A Pollard, Todd A Alonzo, Robert Gerbing

|Dec 02, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Adam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo

Pageof 1

Frequent Collaborators

3 joint publications

Edward Anders Kolb

3 joint publications

Richard Aplenc

3 joint publications

Sarah K Tasian

3 joint publications

Michael R Loken